Medicenna Announces Upcoming Presentations at The Promise of Interleukin-2 Therapy Conference
Medicenna Announces Upcoming Presentations at The Promise of Interleukin-2 Therapy Conference
TORONTO and HOUSTON, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announced today that the Company will present two abstracts, both as oral presentations, at the Promise of Interleukin-2 Therapy Conference, taking place at the Centre International de Conférences Sorbonne Université in Paris, France, from September 4-7, 2024.
2024年8月27日(环球新闻)- Medicenna Therapeutics Corp.(以下简称“Medicenna”或“公司”)(TSX: MDNA,OTCQB: MDNAF)是一家临床阶段免疫疗法公司,专注于超级肽链的开发,今天宣布该公司将在巴黎国际会议中心的Promise of Interleukin-2 Therapy Conference上发表两个摘要,都是口头报告,会议将于2024年9月4-7日在法国巴黎苏尔邦大学国际会议中心举行。
The Company will present preclinical data for the first time on its MDNA209 platform, featuring long-acting, high-affinity IL-2β biased IL-2/IL-15 Super-antagonists with therapeutic potential for autoimmune and graft-versus-host diseases. Additionally, further preclinical data will be presented on MDNA113, the Company's novel first-in-class IL-13Rα2 tumor-targeted and tumor-activated bifunctional anti-PD1-IL-2 Superkine.
公司将首次提供其MDNA209平台的临床前数据,该平台具有长效、高亲和力的IL-2β偏爱IL-2/IL-15超拮抗剂,具有治疗自身免疫性疾病和移植物抗宿主疾病的潜力。此外,还将展示MDNA113的临床前数据,该公司的新型一类IL-13Rα2肿瘤靶向和肿瘤活化双重功能抗PD1-IL-2超肽。
Details for the oral presentations are as follows:
口头报告的详细信息如下:
Title: MDNA209, a High Affinity IL-2β Biased IL-2/IL-15 Super-antagonist, for the Treatment of Autoimmune Diseases
Presenter: Dr. Hardeep Kataria
Session Title: Novel IL-2s, Vectorization and Combination Therapies
Session Date and Time: Friday September 6, 2024; 2 PM CEST (8 AM EST)
标题: MDNA209, 一种高亲和力IL-2β偏爱IL-2/IL-15超拮抗剂,用于治疗自身免疫性疾病
演讲者: Dr. Hardeep Kataria
会议主题: 新型IL-2,载体化和联合疗法
会议日期和时间: 2024年9月6日星期五; 上午8点(东部标准时间)
Title: MDNA113, an IL-13Rα2 Tumor Targeting and Conditionally Activatable anti-PD1-IL-2SK BiSKIT Shows Enhanced Safety and Potent Therapeutic Efficacy
Presenter: Dr. Minh To
Session Title: IL-2 in Cancer Therapy
Session Date and Time: Saturday September 7, 2024; 9 AM CEST (3 AM EST)
标题: MDNA113,一种针对IL-13Rα2肿瘤的封闭式激活型抗PD1-IL-2Sk BiSK,显示出增强的安全性和强效的治疗效果
演讲者: 阮明博士
会议主题: 癌症治疗中的IL-2
会议日期和时间: 2024年9月7日星期六; 上午3点(东部标准时间)
Following the conclusion of the Promise of Interleukin-2 Therapy Conference, copies of the presentations will be available on the "Scientific Presentations" page of Medicenna's website.
在白细胞介素-2疗法承诺会议结束后,演讲的副本将在Medicenna网站的“科学演讲”页面上提供。
About Medicenna Therapeutics
关于医药技术公司Medicenna Therapeutics
Medicenna is a clinical-stage immunotherapy company focused on developing novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first-in-class Empowered Superkines. Medicenna's long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T cells and NK cells. Medicenna's IL-4 Empowered Superkine, bizaxofusp (formerly MDNA55), has been studied in 5 clinical trials enrolling over 130 patients, including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. Bizaxofusp has obtained FastTrack and Orphan Drug status from the FDA and FDA/EMA, respectively. Medicenna's early-stage high-affinity IL-2β biased IL-2/IL-15 Super-antagonists, from its MDNA209 platform, are being evaluated as potential therapies for autoimmune and graft-versus host diseases. Medicenna's early-stage BiSKITs (Bifunctional SuperKine ImmunoTherapies) and the T-MASK (Targeted Metalloprotease Activated SuperKine) programs are designed to enhance the ability of Superkines to treat immunologically "cold" tumors.
Medicenna是一家临床阶段的免疫治疗公司,专注于开发IL-2、IL-4和IL-13超强素的新型、高选择性版本以及独家超强素。Medicenna的长效IL-2超强素MDNA11是下一代IL-2,具有对CD122(IL-2受体β)具有优越的亲和力,且不结合CD25(IL-2受体α),因此优先刺激癌杀伤效应T细胞和NK细胞。Medicenna的IL-4增强超强素bizaxofusp(前MDNA55)已在5项临床试验中研究,招募了130多名患者,包括一项针对复发性GBm的20亿期试验,这是最常见且统一致命的脑癌形式。Bizaxofusp已获得FDA的FastTrack和FDA / EMA的孤儿药物地位。Medicenna的早期高亲和力IL-2β偏好IL-2/IL-15超-拮抗素来自其MDNA209平台,正在评估其作为自身免疫和移植物抗宿主病的潜在疗法。Medicenna的早期BiSKITs(双功能超强素免疫疗法)和t-MASk(靶向金属蛋白酶活化超强素)项目旨在增强超强素治疗免疫“冷”肿瘤的能力。
For more information, please visit , and follow us on Twitter and LinkedIn.
有关更多信息,请访问 ,并在我们之后的推特上关注我们。推特和页面。LinkedIn.
Forward-Looking Statements
前瞻性声明
This news release contains forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include, but are not limited to, express or implied statements regarding the future operations of the Company, estimates, plans, strategic ambitions, partnership activities and opportunities, objectives, expectations, opinions, forecasts, projections, guidance, outlook or other statements that are not historical facts, such as statements on the therapeutic potential and safety profile of MDNA209 and MDNA113. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage pre-clinical or clinical studies may not be indicative of full results or results from later stage or larger scale clinical studies and do not ensure regulatory approval. You should not place undue reliance on these statements, or the scientific data presented.
本新闻稿包含根据适用证券法的前瞻性陈述。前瞻性陈述包括但不限于有关公司未来业务运营、估计、计划、战略雄心、合作伙伴活动与机会、目标、期望、意见、预测、投影、指导、展望或其他陈述,旨在说明MDNA209和MDNA113的治疗潜力和安全性等的表述,并非历史事实。药物研发和商业化面临很高的风险,只有少数研发项目能够商业化。早期临床前或临床研究的结果可能不代表全部结果,也不能确保来自后期或更大规模临床研究的结果或获得监管批准。您不应过度依赖这些陈述或科学数据的呈现。
Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expect", "believe", "seek", "potentially" and similar expressions. and are subject to risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the risks detailed in the latest annual information form of the Company and in other filings made by the Company with the applicable securities regulators from time to time in Canada.
前瞻性声明通常可根据"将"、"可能"、"应"、"预计"、"预期"、"相信"、"寻求"、"潜在"等表达方式进行识别,并受风险和不确定性的影响。不能保证此类声明会被证明准确,实际结果和未来事件可能与该类声明中预期的有重大差异。可能导致实际结果与公司预期有重大差异的重要因素包括公司最新年度信息表格中详细列出的风险,以及公司不时向加拿大适用证券监管机构提交的其他备案文件中的风险。
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date hereof and except as required by law, we do not intend and do not assume any obligation to update or revise publicly any of the included forward-looking statements.
读者应当注意,在准备任何前瞻性信息时所做的假设有可能被证明是不正确的。由于无数已知和未知的风险、不确定性和其他因素,大量已知和未知的风险、不确定性和其他因素可能导致事件或情况导致实际结果与预测结果不同,这是由于公司无法控制。读者被警告不要过度依赖任何前瞻性信息。尽管管理层认为这些信息是合理的,但这些信息有可能被证明是不正确的,实际结果可能与预期的结果有很大不同。本新闻发布所包含的前瞻性声明在此谨此声明。本新闻发布所包含的前瞻性声明是根据此处的日期进行的,除非法律要求,否则我们没有意图并不会承担更新或修订所包含的前瞻性声明的任何义务。
This news release contains hyperlinks to information that is not deemed to be incorporated by reference in this new release.
本新闻稿含有超链接到未被视为本新闻稿参考的信息。
Investor/Media Contact:
投资者/媒体联系方式:
Christina Cameron
Investor Relations, Medicenna Therapeutics
(647) 953-0673
ir@medicenna.com
Christina Cameron
投资者关系,Medicenna Therapeutics
(647) 953-0673
ir@medicenna.com